Avrobio, Inc. AVRO
We take great care to ensure that the data presented and summarized in this overview for AVROBIO, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AVRO
View all-
Atlas Venture Life Science Advisors, LLC4.54MShares$6.31 Million0.73% of portfolio
-
Bml Capital Management, LLC Zionsville, IN4MShares$5.56 Million3.43% of portfolio
-
Adar1 Capital Management, LLC Austin, TX3.95MShares$5.5 Million1.15% of portfolio
-
Verition Fund Management LLC Greenwich, CT1.93MShares$2.68 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.88MShares$2.61 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.24MShares$1.72 Million0.01% of portfolio
-
Newtyn Management, LLC New York, NY1.12MShares$1.56 Million0.31% of portfolio
-
Aisling Capital Management LP New York, NY1.01MShares$1.4 Million0.44% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny888KShares$1.23 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA853KShares$1.19 Million0.13% of portfolio
Latest Institutional Activity in AVRO
Top Purchases
Top Sells
About AVRO
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at AVRO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 14
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
296,882
+5.86%
|
$296,882
$1.3 P/Share
|
|
May 13
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
469,753
+5.12%
|
$469,753
$1.25 P/Share
|
|
Feb 05
2024
|
Azadeh Golipour Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,232
-17.96%
|
$12,232
$1.2 P/Share
|
|
Feb 05
2024
|
Steven Avruch Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,812
-32.93%
|
$10,812
$1.2 P/Share
|
|
Feb 05
2024
|
Erik Ostrowski Interim CEO, President and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,099
-30.91%
|
$13,099
$1.2 P/Share
|
|
Feb 05
2024
|
Essra Ridha Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,953
-51.63%
|
$16,953
$1.2 P/Share
|
|
Feb 01
2024
|
Azadeh Golipour Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,334
+35.41%
|
-
|
|
Feb 01
2024
|
Steven Avruch Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,834
+50.0%
|
-
|
|
Feb 01
2024
|
Erik Ostrowski Interim CEO, President and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,084
+48.61%
|
-
|
|
Feb 01
2024
|
Essra Ridha Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,834
+50.0%
|
-
|
|
Jun 12
2023
|
Azadeh Golipour Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,574
-7.7%
|
$5,574
$1.2 P/Share
|
|
Jan 24
2023
|
Geoffrey Mackay President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
45,999
+19.66%
|
$0
$0.91 P/Share
|
|
Dec 28
2022
|
Geoffrey Mackay President & CEO |
BUY
Bona fide gift
|
Indirect |
245,123
+35.51%
|
-
|
|
Dec 28
2022
|
Geoffrey Mackay President & CEO |
SELL
Bona fide gift
|
Direct |
245,123
-63.32%
|
-
|
|
Dec 23
2022
|
Geoffrey Mackay President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
142,013
+26.84%
|
$0
$0.41 P/Share
|
|
Jul 07
2021
|
Philip J. Vickers Director |
BUY
Open market or private purchase
|
Direct |
4,800
+50.0%
|
$38,400
$8.35 P/Share
|
|
Feb 17
2021
|
Phillip B. Donenberg Director |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$22,000
$11.71 P/Share
|
|
Dec 24
2020
|
Geoffrey Mackay President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+28.98%
|
$0
$0.41 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 767K shares |
|---|---|
| Exercise of conversion of derivative security | 143K shares |
| Payment of exercise price or tax liability | 58.7K shares |
|---|